Ocean Biomedical has been granted patent rights in China for bispecific antibodies targeting CHI3L1 and PD1 to enhance tumor cell cytotoxicity.
Ocean Biomedical, Inc. (NASDAQ: OCEA) based in Providence, R.I., revealed that the China National Intellectual Property Administration (CNIPA) has recently approved a patent for its novel bispecific antibodies that target CHI3L1 and PD1. These antibodies aim to improve T cell-mediated cytotoxicity against cancer cells, infectious diseases, and fibrosis. The announcement was made on March 28, 2025, marking a significant milestone for the company in the treatment of various diseases.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments